Answers are grounded in this paper and cite their sources.
Demonstrates the importance of early lipid management for cardiovascular risk reduction, indicating that statin monotherapy may be insufficient for mixed dyslipidemia.
Strategies aimed at primary prevention provide an outstanding opportunity for reducing the onset and burden of cardiovascular (CV) disease. Lipid abnormalities, including high levels of low-density lipoprotein cholesterol (LDL-C), elevated triglycerides and low levels of high-density lipoprotein cholesterol (HDL-C), are associated with an increased risk of CV events, thereby serving as contributors to this process. By consensus, lowering LDL-C, generally with statin therapy, is the primary target of lipid-lowering therapy. However, statin therapy may be insufficient for patients with mixed dyslipidemia, especially those with insulin resistance syndromes. While the addition of niacin, fibrate or omega-3 fatty acids may be useful in this setting, outcomes data are lacking. Therefore, data from ongoing prospective studies will hopefully resolve this issue and facilitate identification of optimal strategies to augment CV risk reduction.
No takes yet. Share an insight, caveat, or question.
Michael Miller (2009) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: